bluebird bio, Inc. (BLUE): Price and Financial Metrics


bluebird bio, Inc. (BLUE): $2.94

-0.26 (-8.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BLUE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BLUE POWR Grades


  • BLUE scores best on the Growth dimension, with a Growth rank ahead of 89.11% of US stocks.
  • BLUE's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • BLUE ranks lowest in Sentiment; there it ranks in the 2nd percentile.

BLUE Stock Summary

  • With a price/sales ratio of 101.43, bluebird bio Inc has a higher such ratio than 97.61% of stocks in our set.
  • Revenue growth over the past 12 months for bluebird bio Inc comes in at -98.54%, a number that bests only 0.76% of the US stocks we're tracking.
  • In terms of volatility of its share price, BLUE is more volatile than 97.71% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to bluebird bio Inc, a group of peers worth examining would be SAGE, CLNN, FREQ, RETA, and ADCT.
  • BLUE's SEC filings can be seen here. And to visit bluebird bio Inc's official web site, go to www.bluebirdbio.com.

BLUE Valuation Summary

  • In comparison to the median Healthcare stock, BLUE's price/sales ratio is 547.37% higher, now standing at 24.6.
  • BLUE's price/sales ratio has moved down 401.2 over the prior 100 months.
  • Over the past 100 months, BLUE's price/earnings ratio has gone up 14.9.

Below are key valuation metrics over time for BLUE.

Stock Date P/S P/B P/E EV/EBIT
BLUE 2021-08-31 24.6 1.3 -1.5 -1.3
BLUE 2021-08-30 24.0 1.2 -1.4 -1.2
BLUE 2021-08-27 24.4 1.2 -1.5 -1.3
BLUE 2021-08-26 24.1 1.2 -1.4 -1.2
BLUE 2021-08-25 24.5 1.2 -1.5 -1.3
BLUE 2021-08-24 24.0 1.2 -1.4 -1.2

BLUE Growth Metrics

    The 3 year net cashflow from operations growth rate now stands at -313.16%.
  • Its 3 year revenue growth rate is now at 453.25%.
  • Its 2 year net income to common stockholders growth rate is now at -116.66%.
Over the past 34 months, BLUE's revenue has gone down $47,431,000.

The table below shows BLUE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 3.662 -635.639 -819.378
2021-09-30 53.651 -651.107 -864.2
2021-06-30 50.247 -652.948 -842.129
2021-03-31 241.665 -467.557 -621.892
2020-12-31 250.734 -470.351 -618.695
2020-09-30 250.023 -474.134 -642.168

BLUE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BLUE has a Quality Grade of D, ranking ahead of 15.84% of graded US stocks.
  • BLUE's asset turnover comes in at 0.029 -- ranking 353rd of 682 Pharmaceutical Products stocks.
  • NERV, OTLC, and BPMC are the stocks whose asset turnover ratios are most correlated with BLUE.

The table below shows BLUE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.029 0.594 -0.648
2021-03-31 0.129 0.972 -0.495
2020-12-31 0.136 0.978 -0.496
2020-09-30 0.137 0.980 -0.528
2020-06-30 0.132 0.981 -0.546
2020-03-31 0.030 0.934 -0.590

BLUE Price Target

For more insight on analysts targets of BLUE, see our BLUE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $82.33 Average Broker Recommendation 1.92 (Hold)

BLUE Stock Price Chart Interactive Chart >

Price chart for BLUE

BLUE Price/Volume Stats

Current price $2.94 52-week high $35.59
Prev. close $3.20 52-week low $2.92
Day low $2.92 Volume 2,570,152
Day high $3.12 Avg. volume 2,322,789
50-day MA $4.24 Dividend yield N/A
200-day MA $10.88 Market Cap 210.07M

bluebird bio, Inc. (BLUE) Company Bio


Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies. The company was founded in 1992 and is based in Cambridge, Massachusetts.


BLUE Latest News Stream


Event/Time News Detail
Loading, please wait...

BLUE Latest Social Stream


Loading social stream, please wait...

View Full BLUE Social Stream

Latest BLUE News From Around the Web

Below are the latest news stories about bluebird bio Inc that investors may wish to consider to help them evaluate BLUE as an investment opportunity.

The Petri Dish: 2seventy rounds out C-suite, Moderna goes global

The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.

Yahoo | February 17, 2022

Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 15, 2022

bluebird bio Inc. (NASDAQ: BLUE) Dropped -43.31% In 6 Months Heres What Might Happen Next

bluebird bio Inc. (NASDAQ:BLUE)s traded shares stood at 3.51 million during the last session, with the companys beta value hitting 1.60. At the close of trading, the stocks price was $6.91, to imply a decrease of -6.11% or -$0.45 in intraday trading. The BLUE shares 52-week high remains $30.55, putting it -342.11% down since that bluebird bio Inc. (NASDAQ: BLUE) Dropped -43.31% In 6 Months Heres What Might Happen Next Read More »

Marketing Sentinel | February 11, 2022

Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval

Bluebird Bio (BLUE) is a biotech company specialising in lentiviral vector gene therapies for genetic blood disorders. Its portfolio offers potentially curative treatments for conditions such as beta-thalassaemia and sickle cell disease, a previously unheard-of possibility. A previous approval in Europe, however, was brought to a swift end over failure...

Luke Boothman on Seeking Alpha | February 7, 2022

AGF Investments LLC Buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The ...

Investment company AGF Investments LLC (Current Portfolio) buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The Energy Select Sector SPDR Fund, Paratek Pharmaceuticals Inc, Hello Group Inc, sells Industrial Select Sector SPDR, Consumer Staples Select Sector SPDR, Utilities Select Sector SPDR ETF, Microsoft Corp, UnitedHealth Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, AGF Investments LLC.

Yahoo | February 2, 2022

Read More 'BLUE' Stories Here

BLUE Price Returns

1-mo -24.62%
3-mo -49.22%
6-mo N/A
1-year -90.39%
3-year -97.61%
5-year -96.32%
YTD -70.57%
2021 -76.91%
2020 -50.69%
2019 -11.54%
2018 -44.30%
2017 188.65%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8141 seconds.